financetom
Business
financetom
/
Business
/
US CDC backs advisers' recommendation to pull broad support for COVID shot
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US CDC backs advisers' recommendation to pull broad support for COVID shot
Oct 6, 2025 8:33 AM

Oct 6 (Reuters) -

The U.S. Centers for Disease Control and Prevention on

Monday said it had adopted recommendations from a panel of

outside advisors without change, including that COVID-19

vaccines should be administered through shared decision-making

with a healthcare provider.

The new recommendation maintains access for the shot through

health insurance.

The recommendations come at a turbulent time for the CDC,

which recently saw the ouster of its former Director Susan

Monarez after resisting changes to vaccine policy advanced by

Health Secretary Robert F. Kennedy Jr.

The acting director of the CDC, Jim O'Neill, also signed

off on its advisers' recommendations against use of the combined

measles-mumps-rubella-varicella vaccine before the age of 4

years. Instead, separate shots will be given for

measles-mumps-rubella and varicella, commonly known as

chickenpox.

The immunization schedules will be updated on the CDC

website by Tuesday, the agency said.

Earlier this year, CDC said COVID vaccination in healthy

children aged 6 months to 17 years should follow shared clinical

decision by a child's parents and their healthcare provider,

after Kennedy said the recommendations for such children and

pregnant women would be dropped.

Kennedy, a long-time vaccine skeptic, has sought to rewrite

the country's immunization policies through a series of

far-reaching actions, including dismantling the national vaccine

advisory board and later reconstituting it with hand-picked

experts who share his opposition to COVID shots.

The U.S. Food and Drug Administration, in August, had

cleared updated COVID-19 vaccines for everyone over age 65 but

limited its approval for younger people to those with health

risks.

The three approved COVID shots are made by Pfizer ( PFE )

with German partner BioNTech, Moderna ( MRNA ), and

Novavax ( NVAX ) with Sanofi.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Yum China Says it Opened Nine Little Sheep Restaurants in China in May
Yum China Says it Opened Nine Little Sheep Restaurants in China in May
May 31, 2024
07:57 AM EDT, 05/31/2024 (MT Newswires) -- Yum China Holdings ( YUMC ) said Friday its Chinese business unit opened nine Little Sheep restaurants across China in May. Internationally, Yum China ( YUMC ) said a new Little Sheep restaurant opened in the Meadowlands shopping complex in East Rutherford, New Jersey in March. Yum China ( YUMC ) operates the...
Aimia Files Information Circular With Proposed Director Nominees Ahead of Shareholders' Meeting
Aimia Files Information Circular With Proposed Director Nominees Ahead of Shareholders' Meeting
May 31, 2024
07:47 AM EDT, 05/31/2024 (MT Newswires) -- Aimia ( AIMFF ) , which is battling with its largest shareholder Mithaq Capital to maintain control of its board, has filed its management information circular and slate of director nominees with Canadian regulatory authorities ahead of its annual shareholders' meeting on June 26. Yesterday, Mithaq proposed a slate of six nominees to...
Deutsche Bank sees slightly lower fixed income revenue in Q2
Deutsche Bank sees slightly lower fixed income revenue in Q2
May 31, 2024
BERLIN (Reuters) - Deutsche Bank expects a slight decline in its fixed-income business this quarter, but still sees overall revenue of 30 billion euros ($32.56 billion) in 2024, the chief financial officer of Germany's largest bank said. Looking at fixed income and currencies, we would expect that to come in slightly lower in the second quarter versus the prior year's...
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
May 31, 2024
May 31 (Reuters) - Sanofi and partner Regeneron Pharmaceuticals ( REGN ) have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review. French drugmaker Sanofi and its U.S. partner have been counting on expanding the use of the drug as an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved